Latest news articles

Added 1 month ago Drug news

Stelara filed with EMA for ulcerative colitis.- Janssen.

Janssen has submitted a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval of Stelara (ustekinumab)...

Added 1 month ago Drug news

NICE approves Xeljanz for ulcerative colitis.- Pfizer.

The National Institute for Health and Care Excellence (NICE) has approved Xeljanz (tofacitinib), from Pfizer, for adults with moderate to...

Added 2 months ago Drug news

ABP 710 filed with FDA as biosimilar to Remicade in various indications.- Amgen.

Amgen announced the submission of a Biologics License Application (BLA) to the FDA for ABP 710, a biosimilar candidate to...

Search all news articles for Regional enteritis and ulcerative colitis

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Inflammatory bowel disease assessment tools

Inflammatory bowel disease assessment tools

'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.

Load more


Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition

Chronic diarrhoea is a common problem, hence clear guidance on investigations is required. This is an updated guideline from 2003 for the investigations of chronic diarrhoea...

Added 8 months ago

ECCO-ESCP Consensus on Surgery for Crohn’s Disease

The goal of this consensus initiated by the European Crohn’s and Colitis Organisation [ECCO] and European Society of Colo-Proctology [ESCP] was to establish European consensus guidelines for the surgical treatment of Crohn’s disease [CD].

Added 7 months ago

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

The guideline has been condensed into two papers,[...] the second describing current therapeutic management [treatment of active disease and maintenance of medically induced remission].

Added 7 months ago

Search all guidelines for Regional enteritis and ulcerative colitis

Journal articles

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.

Objective: To evaluate the safety of adalimumab in pediatric patients who participated in clinical trials of juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and pediatric enthesitis-related arthritis)...

Added 5 months ago

Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.

Golimumab (GLB) is an antitumour necrosis factor-α (anti-TNF) therapy that has shown efficacy as induction and maintenance therapy for ulcerative colitis (UC).

Added 6 months ago

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.

We performed a randomized placebo-controlled trial to determine the long-term efficacy and safety of a single local administration of allogeneic expanded adipose-derived stem cells (Cx601) in patients with Crohn’s disease and perianal fistulas.

Added 8 months ago

Search all journal articles for Regional enteritis and ulcerative colitis

Clinical trials

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness

Vedolizumab is a new medication being used for the treatment of Crohn's disease and Ulcerative colitis. It works by blocking specific white blood cells (alpha 4-beta7 lymphocytes) from migrating to areas of inflammation in...

Added 1 year ago

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to Immunomodulators or anti-Tumor Necrosis Factor...

Added 1 year ago

Personalising Anti-TNF Therapy in Crohns Disease (PANTS)

The primary objective of this study is to investigate the mechanisms that underlie primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADRs) to anti-TNF drugs in patients with active luminal Crohn's disease.

Added 1 year ago

Search all clinical trials for Regional enteritis and ulcerative colitis
Stephen Smith

Scientific Services Director at Digital Medical Communications. 

UEGW 2018 | Day 5 Highlights

A number of presentations and abstracts shared updates on the latest developments for new treatments and therapies, some of which are pioneering new modes of action. Here we look to the horizon, gaining insights into the latest data for novel treatments targeting Janus kinase (JAK) signalling, MAdCAM-1-mediated adhesion and the interleukin IL-23.